Dr. Eric Verdin is the President and CEO of the Buck Institute for Research on Aging – a pioneering biomedical research institute dedicated to ageing and age-related disease.

A native of Belgium, Dr. Verdin received his Doctorate of Medicine (MD) from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also currently a professor of medicine at the University of California, San Francisco.

He joined the Gladstone Institute of Virology and Immunology in 1997, becoming the associate director in 2004. In 2016 Dr. Verdin established his laboratory at the Buck Institute for Research on Aging to study the relationship between ageing and the immune system.

He is in the top one percent of cited scientists and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He has published more than 220 scientific papers and holds more than 15 patents. He is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. He also serves on the advisory council of the National Institute on Drug Abuse at the National Institutes of Health.

Dr. Verdin has extensive experience working with biotech companies, including Novartis, Roche, Pfizer, and now Hooke London.